Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1223Neoplasms 1041Carcinoma, Non-Small-Cell Lung 755Prostatic Neoplasms 693Colorectal Neoplasms 593Lung Neoplasms 574Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 399Neoplasm Metastasis 387Multiple Myeloma 374Ovarian Neoplasms 372Stomach Neoplasms 317Carcinoma, Hepatocellular 303Melanoma 282Recurrence 281Brain Neoplasms 281Squamous Cell Carcinoma of Head and Neck 268Head and Neck Neoplasms 237Endometrial Neoplasms 235Glioblastoma 234Triple Negative Breast Neoplasms 230Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Uterine Cervical Neoplasms 225Lymphoma 224Hematologic Neoplasms 200Sarcoma 199Urinary Bladder Neoplasms 197Esophageal Neoplasms 191Carcinoma, Renal Cell 190Lymphoma, Non-Hodgkin 176

Interventions

gedatolisib 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Genital Diseases, Male × 1 year × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡